Why the study?
Other treatments for lipoprotein lipase deficiency are costly with limiting side effects, and while orlistat has proven safe and effective in children, no studies have evaluated it in adults.
Does orlistat effectively treat hypertriglyceridemia-induced pancreatitis in an adult with LPL deficiency?
Does orlistat effectively treat hypertriglyceridemia-induced pancreatitis in an adult with LPL deficiency?
Orlistat may be a potential adjunctive treatment option for LPL deficiency in adults to prevent recurrent hypertriglyceridemia-induced pancreatitis.
Answers are grounded in this paper and cite their sources.
Orlistat may reduce pancreatitis recurrence in LPL deficiency; hypothesis-generating and requires prospective trials before practice change.
Background: Patients with lipoprotein lipase (LPL) deficiency, an inherited disorder, develop hypertriglyceridemia, which can lead to recurrent pancreatitis. The mainstay of therapy is medical nutritional therapy. Case Report: We present the case of a 35-year-old woman with LPL deficiency who experienced recurrent hospitalizations for hypertriglyceridemia-induced pancreatitis, which was effectively treated with orlistat. Discussion: Other agents that have been studied for the treatment of LPL deficiency are costly and have limiting side effects. Studies have shown orlistat to be safe and effective for the treatment of LPL deficiency in children. No studies have been performed in adults with LPL deficiency. Conclusion: Orlistat may be a potential adjunctive treatment option for LPL deficiency in adults, given its availability and favorable safety profile. Further research regarding orlistat in the setting of LPL deficiency is needed.
No takes yet. Share an insight, caveat, or question.
Jarrett et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: